JS
Highly rated in
12
conditions
Highly rated in
12
conditions
Check Dr. Jennifer M. Scalici's experience treating your condition:
About Dr. Jennifer M. Scalici

Jennifer Scalici is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Mobile, Alabama. Scalici has been practicing medicine for over 17 years and is highly rated in 12 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Hysterectomy. She is licensed to treat patients in Alabama and Illinois. Scalici is currently accepting new patients.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 3 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Jennifer M. Scalici it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Jennifer M. Scalici accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Molina Healthcare
  •  UnitedHealthcare
  •  Magnolia Health

Call to see if your plan is accepted.
Locations
1660 Spring Hill Ave, Mobile, AL 36604
Background & Education
Graduate Institution
University Of Alabama School Of Medicine, 2005
Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in AL
Hospital Affiliations
Mobile Infirmary
USA Childrens & Womens Hospital
USA Health University Hospital
Arbor Health Morton Hospital
Thomas Hospital
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


3 Clinical Trials

A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
View 2 Less Clinical Trial -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors